Enzyme Inhibitors Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 3.95 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Enzyme Inhibitors Market Analysis
The enzyme inhibitors market is projected to register a CAGR of 3.95% during the forecast period.
- The COVID-19 pandemic had a significant impact on the enzyme inhibitors market. With the emergence of the infectious and virulent coronavirus in the past year, it became essential to understand the cause of the infection. Enzyme inhibitors have helped investigate the enzymes responsible for allowing viral entry and the potential for inhibition to reduce the severity or prevent COVID-19.
- For instance, a study published by Elsevier Public Health Emergency Collection in October 2021 identified enzymes responsible for SARS-CoV-2 viral entry into cells and compounds proposed to inhibit viral access to treat COVID-19 infection. Thus, the increasing number of COVID-19 cases led to a growing demand for enzyme inhibitors. However, due to the increased vaccination and availability of other drugs for COVID-19 treatment, the market has lost some traction gained during the pandemic. Nevertheless, the market is expected to have favorable growth due to the presence of other infections over the forecast period.
- The growth of the enzyme inhibitors market can also be attributed to the increasing demand for effective and accurate drugs, the exponential rise in diseases like cancer, and rising global agricultural activities and pharmaceutical establishments. For example, cancer is a complex multifactorial disease that results from alterations in many physiological and biochemical functions. Cancer cells can acquire multidrug resistance to conventional anticancer drugs, resulting in tumor relapse. Thus, there is a continuous need to discover new and effective anticancer drugs, which is expected to increase the demand for enzyme inhibitors and drive the market's growth. The rising trend of launches, acquisitions, and collaborations in the pharmaceutical industry also drives the market's growth.
- The Cancer Facts & Figures 2023 data published by the American Cancer Society shows an estimated 1.9 million new cancer cases diagnosed and 609,820 cancer deaths in the US in 2023. The exponential rise in the prevalence of diseases like cancer is expected to drive the market's growth. In April 2021, Artios Pharma Limited collaborated with Novartis International AG to uncover and verify new generation DDR targets to advance Novartis' Radioligand Therapies. Additionally, in March 2021, Amgen Inc acquired Rodeo Therapeutics Corporation, recognizing the potential value and differentiated profile of Rodeo's lead 15-prostaglandin dehydrogenase inhibitor program.
- However, the patent expirations of enzyme inhibitor drugs and the availability of low-cost generic drugs restrain the market growth. Overall, the enzyme inhibitors market is expected to grow over the forecast period, driven by the factors mentioned above.
Enzyme Inhibitors Market Trends
Kinase Inhibitors Segment Is Expected to Hold a Significant Share in the Enzyme Inhibitors Market
- Kinase inhibitors are a class of enzyme inhibitors that obstruct the activity of one or more protein kinase enzymes. Protein kinases are enzymes that add a phosphate group to a protein, altering its function. Certain types of kinases are more active in various cancer cells, and blocking these kinases may help impede cancer cell growth.
- The escalating prevalence of target diseases such as cancer and cardiovascular disease, as well as the increase in kinase inhibitors for treating these diseases, have been driving the growth of this segment. For instance, a study published by the British Heart Foundation in February 2023 indicated that around 7.6 million people in the United Kingdom were living with heart disease in 2021.
- Moreover, an article published by the National Library of Medicine (NLM) in November 2022 revealed that 72 Food and Drug Administration (FDA)-approved therapeutic agents target about two dozen protein kinases, with three of these drugs being approved in 2022. Of the approved drugs, twelve target protein-serine/threonine protein kinases, four are directed against dual specificity protein kinases (MEK1/2), sixteen block nonreceptor protein-tyrosine kinases, and 40 target receptor protein-tyrosine kinases. Sixty-two of these drugs are prescribed for the treatment of neoplasms.
- Four drugs (abrocitinib, baricitinib, tofacitinib, and upadacitinib) are used to treat inflammatory diseases (atopic dermatitis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, and ulcerative colitis). The increasing availability of kinase inhibitors for treating target diseases is expected to drive segmental growth.
- Furthermore, acquisitions, partnerships, mergers, and collaborations by key players in the market are expected to boost the segmental market. For example, in March 2021, Pfizer Inc. received United States Food and Drug Administration (US FDA) approval for a supplemental new drug application (sNDA) for LORBRENA (lorlatinib), a TKI, expanding the indication to include first-line treatment of people with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). LORBRENA is indicated for adults with metastatic NSCLC whose tumors are ALK-positive as detected by an FDA-approved test.
- Thus, all of the aforementioned factors, including the growing prevalence of target diseases such as cancer and cardiovascular disease, the increase in kinase inhibitors for treating these diseases, and the mergers and partnerships of key players, are expected to contribute to the growth of this segment over the forecast period.
North America Is Expected to Hold a Significant Share in the Enzyme Inhibitors Market
- The growth of North America's market is driven by several factors, including a well-established healthcare infrastructure and increased government initiatives that offer attractive reimbursement policies. Additionally, the rising incidence of cancer is a significant factor driving the enzyme inhibitors market's development.
- According to the American Cancer Society's 2023 update, more than 1.9 million new cancer cases are expected to be diagnosed in the United States this year, excluding basal and squamous cell skin cancers and carcinoma in situ, except for the urinary bladder. Similarly, the Canadian Cancer Statistics 2021 report released in November 2021 estimated that two out of five Canadians would be diagnosed with cancer in their lifetime, with 229,200 Canadians diagnosed in 2021. Consequently, the growing prevalence of cancer in North America is expected to have a substantial impact on the market's expansion.
- In addition, the introduction of innovative products using enzyme inhibitors to treat multiple conditions is expected to drive market growth. For example, in July 2021, Ocular Therapeutix Inc. initiated the first patient in the United States Phase 1 clinical trial of OTX-TKI (axitinib intravitreal implant) to treat wet age-related macular degeneration (wet AMD). Additionally, in June 2022, Pfizer Inc. submitted a New Drug Application (N.D.A.) to the USFDA for the approval of PAXLOVID (nirmatrelvir and ritonavir tablets) for high-risk patients who are likely to progress to severe illness from COVID-19. As a result, ongoing clinical trial processes in this market are expected to promote its growth.
- In summary, the factors mentioned above, including a developed healthcare infrastructure, increased government initiatives, and the growing incidence of cancer, are expected to contribute significantly to North America's strong growth in this market over the forecast period.
Enzyme Inhibitors Industry Overview
The market for enzyme inhibitors is moderately concentrated, with companies operating globally and regionally. The competitive landscape includes an analysis of a few international as well as local companies that hold significant market shares and are well-known, such as Abbott Laboratories, Amgen Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Cipla USA Inc., F. Hoffmann-La Roche, Novartis AG, Pfizer Inc., and others.
Enzyme Inhibitors Market Leaders
-
Abbott Laboratories
-
AstraZeneca PLC
-
Bayer Ag
-
Boehringer Ingelheim International GmbH
-
Amgen Inc.
*Disclaimer: Major Players sorted in no particular order
Enzyme Inhibitors Market News
- In January 2023, AstraZeneca announced its acquisition of CinCor Pharma, Inc. The acquisition aims to enhance AstraZeneca's cardiorenal pipeline by including CinCor's candidate drug, baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) for reducing blood pressure in cases of treatment-resistant hypertension.
- In April 2022, Daewon Pharmaceutical launched Escorten, which is one of Korea's first proton-pump inhibitor drugs. Escorten contains esomeprazole magnesium trihydrate and is available in a 10 mg dosage.
Enzyme Inhibitors Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Demand for Effective and Accurate Drugs
- 4.2.2 Exponential Rise in the Incidence of Diseases like Cancer
- 4.2.3 Rising Global Agricultural Activities and Pharmaceutical Establishments
-
4.3 Market Restraints
- 4.3.1 Patent Expirations of Enzyme Inhibitor Drugs
- 4.3.2 Low-cost Generic Drugs
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Type
- 5.1.1 Proton Pump Inhibitors [PPIs]
- 5.1.2 Protease Inhibitors
- 5.1.3 Reverse Transcriptase Inhibitors
- 5.1.4 Kinase Inhibitors
- 5.1.5 Other Types
-
5.2 By Application
- 5.2.1 Medical
- 5.2.2 Agriculture
- 5.2.3 Other Applications
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 United Kingdom
- 5.3.2.2 France
- 5.3.2.3 Germany
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 India
- 5.3.3.2 China
- 5.3.3.3 Japan
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPANY PROFILES AND COMPETITIVE LANDSCAPE
- 6.1 Abbott Laboratories
- 6.2 Amgen Inc.
- 6.3 AstraZeneca PLC
- 6.4 Bayer AG
- 6.5 Boehringer Ingelheim International GmbH
- 6.6 Bristol-Myers Squibb
- 6.7 Cipla Inc.
- 6.8 F. Hoffmann-La Roche
- 6.9 Novartis AG
- 6.10 Pfizer Inc.
- 6.11 Takeda Pharmaceutical Company Limited
- 6.12 GlaxoSmithKline Pharmaceuticals
- 6.13 Merck & Co.
- 6.14 ACROBiosystems Group
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityEnzyme Inhibitors Industry Segmentation
As per the scope of this report, enzyme inhibitors are a molecule that binds to an enzyme reversibly or irreversibly and decreases or completely inhibits its catalytic activity. Enzyme inhibitors are naturally occurring and made up of protein.
The enzyme inhibitors market is segmented by type (proton pump inhibitors (PPIs), protease inhibitors, reverse transcriptase inhibitors, kinase inhibitors, and other types), application (medical, agriculture, and other applications), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally.
The report offers the value (in USD) for the above segments.
| By Type | Proton Pump Inhibitors [PPIs] | |
| Protease Inhibitors | ||
| Reverse Transcriptase Inhibitors | ||
| Kinase Inhibitors | ||
| Other Types | ||
| By Application | Medical | |
| Agriculture | ||
| Other Applications | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | United Kingdom |
| France | ||
| Germany | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | India |
| China | ||
| Japan | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Enzyme Inhibitors Market Research FAQs
What is the current Enzyme Inhibitors Market size?
The Enzyme Inhibitors Market is projected to register a CAGR of 3.95% during the forecast period (2024-2029)
Who are the key players in Enzyme Inhibitors Market?
Abbott Laboratories, AstraZeneca PLC, Bayer Ag, Boehringer Ingelheim International GmbH and Amgen Inc. are the major companies operating in the Enzyme Inhibitors Market.
Which is the fastest growing region in Enzyme Inhibitors Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Enzyme Inhibitors Market?
In 2024, the North America accounts for the largest market share in Enzyme Inhibitors Market.
What years does this Enzyme Inhibitors Market cover?
The report covers the Enzyme Inhibitors Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Enzyme Inhibitors Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Europe Nuclear Medicine Industry Report
Statistics for the 2024 Europe Nuclear Medicine market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Europe Nuclear Medicine analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
